Profitability
This table compares PaxMedica and MorphoSys’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PaxMedica | N/A | -3,167.89% | -560.35% |
| MorphoSys | -226.79% | -694.31% | -22.55% |
Risk and Volatility
PaxMedica has a beta of -0.99, indicating that its stock price is 199% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.
Earnings and Valuation
This table compares PaxMedica and MorphoSys”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PaxMedica | N/A | N/A | -$18.29 million | ($6.09) | 0.00 |
| MorphoSys | $238.28 million | 11.99 | -$205.35 million | ($3.48) | -5.45 |
PaxMedica has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than PaxMedica, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
4.9% of PaxMedica shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 1.0% of PaxMedica shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
MorphoSys beats PaxMedica on 6 of the 10 factors compared between the two stocks.
About PaxMedica
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.
About MorphoSys
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.
Receive News & Ratings for PaxMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PaxMedica and related companies with MarketBeat.com's FREE daily email newsletter.
